Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 2/20 | 0.39 |
| ▸ | MTNR1B | P49286 | 2/20 | 0.39 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.37 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.37 |
| ▸ | SLC2A1 | P11166 | 5/20 | 0.37 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.36 |
| ▸ | TSPO | P30536 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14046552 | 0.93 | MTNR1A (0.37) | MTNR1AMTNR1BGABRA2GABRB2SLC2A1 | |
| SCHEMBL14046526 | 0.91 | MTNR1B (0.41) | MTNR1AMTNR1BGABRA2GABRB2SLC2A1 | |
| SCHEMBL4671352 | 0.89 | SLC2A1 (0.48) | MTNR1AMTNR1BSLC2A1 | |
| SCHEMBL14046437 | 0.85 | SLC2A1 (0.42) | MTNR1AMTNR1BGABRA2GABRB2SLC2A1 | |
| SCHEMBL4671342 | 0.82 | SLC2A1 (0.41) | MTNR1AMTNR1BGABRA2GABRB2SLC2A1 | |
| SCHEMBL4669923 | 0.82 | SLC2A1 (0.46) | MTNR1AMTNR1BSLC2A1 | |
| SCHEMBL4669886 | 0.81 | MTNR1B (0.47) | MTNR1AMTNR1BSLC2A1 | |
| SCHEMBL4671517 | 0.80 | SLC2A1 (0.44) | MTNR1AMTNR1BSLC2A1TSPO | |
| SCHEMBL4669677 | 0.79 | SLC2A1 (0.46) | MTNR1AMTNR1BSLC2A1 | |
| SCHEMBL4671511 | 0.78 | MTNR1A (0.47) | MTNR1AMTNR1BSLC2A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2008116665-A1 | SUBSTITUTED IMIDAZOPYRIDINE DERIVATIVES AS MELANOCORTIN-4 RECEPTOR ANTAGONISTS | SANTHERA PHARMACEUTICALS (SCHWEIZ) AG (CH) | 2008-10-02 | — | — | WO | disclosed |